Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Growth 2022-2028
As the global economy mends, the 2021 growth of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs will have significant change from previous year. According to our latest study, the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market size is USD million in 2022 from USD 1357.9 million in 2021, with a change of % between 2021 and 2022. The global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market size will reach USD 2837 million in 2028, growing at a CAGR of 11.1% over the analysis period.
The United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market, reaching US$ million by the year 2028. As for the Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs players cover Bausch Health, Allergan, Sebela Pharmaceuticals, and Astellas Pharmaceuticals, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
XIFAXAN
Viberzi
Lotronex
Other
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.
Hospitals Pharmacy
Retail Pharmacy
Other
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include
Bausch Health
Allergan
Sebela Pharmaceuticals
Astellas Pharmaceuticals
Amneal Pharms
Pharscin Pharma
Frequently Asked Questions
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
- By Type
- By Application
- By Region
- By Country
- By Manufacturer
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Country/Region, 2017, 2022 & 2028
2.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Type
2.2.1 XIFAXAN
2.2.2 Viberzi
2.2.3 Lotronex
2.2.4 Other
2.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type
2.3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2017-2022)
2.3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Market Share by Type (2017-2022)
2.3.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sale Price by Type (2017-2022)
2.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Sales Channel
2.4.1 Hospitals Pharmacy
2.4.2 Retail Pharmacy
2.4.3 Other
2.5 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel
2.5.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sale Market Share by Sales Channel (2017-2022)
2.5.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Market Share by Sales Channel (2017-2022)
2.5.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sale Price by Sales Channel (2017-2022)
3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Company
3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Breakdown Data by Company
3.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Annual Sales by Company (2020-2022)
3.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Company (2020-2022)
3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Annual Revenue by Company (2020-2022)
3.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Company (2020-2022)
3.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Company (2020-2022)
3.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sale Price by Company
3.4 Key Manufacturers Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Location Distribution
3.4.2 Players Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Geographic Region
4.1 World Historic Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Geographic Region (2017-2022)
4.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Annual Revenue by Geographic Region
4.2 World Historic Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country/Region (2017-2022)
4.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Annual Sales by Country/Region (2017-2022)
4.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Annual Revenue by Country/Region
4.3 Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth
4.4 APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth
4.5 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth
4.6 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth
5 Americas
5.1 Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country
5.1.1 Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2017-2022)
5.1.2 Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2017-2022)
5.2 Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type
5.3 Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region
6.1.1 APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2017-2022)
6.1.2 APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2017-2022)
6.2 APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type
6.3 APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Country
7.1.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2017-2022)
7.1.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2017-2022)
7.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type
7.3 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Country
8.1.1 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2017-2022)
8.1.2 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2017-2022)
8.2 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type
8.3 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
10.3 Manufacturing Process Analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
10.4 Industry Chain Structure of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distributors
11.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Customer
12 World Forecast Review for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Geographic Region
12.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size Forecast by Region
12.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Forecast by Region (2023-2028)
12.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Forecast by Type
12.7 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Forecast by Sales Channel
13 Key Players Analysis
13.1 Bausch Health
13.1.1 Bausch Health Company Information
13.1.2 Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Offered
13.1.3 Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Bausch Health Main Business Overview
13.1.5 Bausch Health Latest Developments
13.2 Allergan
13.2.1 Allergan Company Information
13.2.2 Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Offered
13.2.3 Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 Allergan Main Business Overview
13.2.5 Allergan Latest Developments
13.3 Sebela Pharmaceuticals
13.3.1 Sebela Pharmaceuticals Company Information
13.3.2 Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Offered
13.3.3 Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Sebela Pharmaceuticals Main Business Overview
13.3.5 Sebela Pharmaceuticals Latest Developments
13.4 Astellas Pharmaceuticals
13.4.1 Astellas Pharmaceuticals Company Information
13.4.2 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Offered
13.4.3 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Astellas Pharmaceuticals Main Business Overview
13.4.5 Astellas Pharmaceuticals Latest Developments
13.5 Amneal Pharms
13.5.1 Amneal Pharms Company Information
13.5.2 Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Offered
13.5.3 Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Amneal Pharms Main Business Overview
13.5.5 Amneal Pharms Latest Developments
13.6 Pharscin Pharma
13.6.1 Pharscin Pharma Company Information
13.6.2 Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Offered
13.6.3 Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Pharscin Pharma Main Business Overview
13.6.5 Pharscin Pharma Latest Developments
14 Research Findings and Conclusion
List of Tables
Table 1. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of XIFAXAN
Table 4. Major Players of Viberzi
Table 5. Major Players of Lotronex
Table 6. Major Players of Other
Table 7. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2017-2022) & (K Units)
Table 8. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2017-2022)
Table 9. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2017-2022) & ($ million)
Table 10. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type (2017-2022)
Table 11. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sale Price by Type (2017-2022) & (USD/Unit)
Table 12. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2017-2022) & (K Units)
Table 13. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2017-2022)
Table 14. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Sales Channel (2017-2022)
Table 15. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Sales Channel (2017-2022)
Table 16. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sale Price by Sales Channel (2017-2022) & (USD/Unit)
Table 17. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Company (2020-2022) & (K Units)
Table 18. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Company (2020-2022)
Table 19. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Company (2020-2022) ($ Millions)
Table 20. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Company (2020-2022)
Table 21. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sale Price by Company (2020-2022) & (USD/Unit)
Table 22. Key Manufacturers Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Producing Area Distribution and Sales Area
Table 23. Players Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Products Offered
Table 24. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Geographic Region (2017-2022) & (K Units)
Table 28. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share Geographic Region (2017-2022)
Table 29. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Geographic Region (2017-2022) & ($ millions)
Table 30. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Geographic Region (2017-2022)
Table 31. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country/Region (2017-2022) & (K Units)
Table 32. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country/Region (2017-2022)
Table 33. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country/Region (2017-2022) & ($ millions)
Table 34. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country/Region (2017-2022)
Table 35. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2017-2022) & (K Units)
Table 36. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2017-2022)
Table 37. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2017-2022) & ($ Millions)
Table 38. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2017-2022)
Table 39. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2017-2022) & (K Units)
Table 40. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2017-2022)
Table 41. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2017-2022) & (K Units)
Table 42. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2017-2022)
Table 43. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2017-2022) & (K Units)
Table 44. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2017-2022)
Table 45. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2017-2022) & ($ Millions)
Table 46. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region (2017-2022)
Table 47. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2017-2022) & (K Units)
Table 48. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2017-2022)
Table 49. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2017-2022) & (K Units)
Table 50. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2017-2022)
Table 51. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2017-2022) & (K Units)
Table 52. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2017-2022)
Table 53. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2017-2022) & ($ Millions)
Table 54. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2017-2022)
Table 55. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2017-2022) & (K Units)
Table 56. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2017-2022)
Table 57. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2017-2022) & (K Units)
Table 58. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2017-2022)
Table 59. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2017-2022) & (K Units)
Table 60. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2017-2022)
Table 61. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2017-2022) & ($ Millions)
Table 62. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2017-2022)
Table 63. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2017-2022) & (K Units)
Table 64. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2017-2022)
Table 65. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2017-2022) & (K Units)
Table 66. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2017-2022)
Table 67. Key Market Drivers & Growth Opportunities of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
Table 68. Key Market Challenges & Risks of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
Table 69. Key Industry Trends of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
Table 70. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Raw Material
Table 71. Key Suppliers of Raw Materials
Table 72. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distributors List
Table 73. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Customer List
Table 74. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Region (2023-2028) & (K Units)
Table 75. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Forecast by Region
Table 76. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Region (2023-2028) & ($ millions)
Table 77. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share Forecast by Region (2023-2028)
Table 78. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Country (2023-2028) & (K Units)
Table 79. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Country (2023-2028) & ($ millions)
Table 80. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Region (2023-2028) & (K Units)
Table 81. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Region (2023-2028) & ($ millions)
Table 82. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Country (2023-2028) & (K Units)
Table 83. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Country (2023-2028) & ($ millions)
Table 84. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Country (2023-2028) & (K Units)
Table 85. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Country (2023-2028) & ($ millions)
Table 86. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Type (2023-2028) & (K Units)
Table 87. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share Forecast by Type (2023-2028)
Table 88. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 89. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share Forecast by Type (2023-2028)
Table 90. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Sales Channel (2023-2028) & (K Units)
Table 91. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share Forecast by Sales Channel (2023-2028)
Table 92. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Sales Channel (2023-2028) & ($ Millions)
Table 93. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share Forecast by Sales Channel (2023-2028)
Table 94. Bausch Health Basic Information, Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 95. Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Offered
Table 96. Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 97. Bausch Health Main Business
Table 98. Bausch Health Latest Developments
Table 99. Allergan Basic Information, Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 100. Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Offered
Table 101. Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 102. Allergan Main Business
Table 103. Allergan Latest Developments
Table 104. Sebela Pharmaceuticals Basic Information, Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 105. Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Offered
Table 106. Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 107. Sebela Pharmaceuticals Main Business
Table 108. Sebela Pharmaceuticals Latest Developments
Table 109. Astellas Pharmaceuticals Basic Information, Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 110. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Offered
Table 111. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 112. Astellas Pharmaceuticals Main Business
Table 113. Astellas Pharmaceuticals Latest Developments
Table 114. Amneal Pharms Basic Information, Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 115. Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Offered
Table 116. Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 117. Amneal Pharms Main Business
Table 118. Amneal Pharms Latest Developments
Table 119. Pharscin Pharma Basic Information, Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 120. Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Offered
Table 121. Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2022)
Table 122. Pharscin Pharma Main Business
Table 123. Pharscin Pharma Latest Developments
List of Figures
Figure 1. Picture of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
Figure 2. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate 2017-2028 (K Units)
Figure 7. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of XIFAXAN
Figure 10. Product Picture of Viberzi
Figure 11. Product Picture of Lotronex
Figure 12. Product Picture of Other
Figure 13. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type in 2021
Figure 14. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type (2017-2022)
Figure 15. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumed in Hospitals Pharmacy
Figure 16. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Hospitals Pharmacy (2017-2022) & (K Units)
Figure 17. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumed in Retail Pharmacy
Figure 18. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Retail Pharmacy (2017-2022) & (K Units)
Figure 19. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumed in Other
Figure 20. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Other (2017-2022) & (K Units)
Figure 21. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2017-2022)
Figure 22. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Sales Channel in 2021
Figure 23. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market by Company in 2021 ($ Million)
Figure 24. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Company in 2021
Figure 25. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Geographic Region (2017-2022)
Figure 26. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Geographic Region in 2021
Figure 27. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2017-2022)
Figure 28. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country/Region in 2021
Figure 29. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales 2017-2022 (K Units)
Figure 30. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue 2017-2022 ($ Millions)
Figure 31. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales 2017-2022 (K Units)
Figure 32. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue 2017-2022 ($ Millions)
Figure 33. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales 2017-2022 (K Units)
Figure 34. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue 2017-2022 ($ Millions)
Figure 35. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales 2017-2022 (K Units)
Figure 36. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue 2017-2022 ($ Millions)
Figure 37. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country in 2021
Figure 38. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country in 2021
Figure 39. United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 40. Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 41. Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 42. Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 43. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region in 2021
Figure 44. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Regions in 2021
Figure 45. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 46. Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 47. South Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 48. Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 49. India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 50. Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 51. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country in 2021
Figure 52. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country in 2021
Figure 53. Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 54. France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 55. UK Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 56. Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 57. Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 58. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country in 2021
Figure 59. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country in 2021
Figure 60. Egypt Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 61. South Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 62. Israel Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 63. Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 64. GCC Country Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth 2017-2022 ($ Millions)
Figure 65. Manufacturing Cost Structure Analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in 2021
Figure 66. Manufacturing Process Analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
Figure 67. Industry Chain Structure of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
Figure 68. Channels of Distribution
Figure 69. Distributors Profiles
